Q3 Earnings Reaction: Recent discussions on X about Hims & Hers Health (HIMS) have centered on the company’s third-quarter earnings, which showed strong sales growth but mixed profitability. Many users expressed optimism about the revenue increase of over 70%, though some noted concerns over profit margins. The stock experienced volatility post-earnings, with initial gains fading as the market digested the numbers.
Strategic Expansion Buzz: Another hot topic on X is HIMS’ focus on new verticals like peptides and international markets. Posts highlight excitement over the potential for long-term growth, with some calling it a transformative move in telehealth. However, a few voices caution that short-term growth may slow due to heavy investments in these areas.
Healthcare Disruption Hype: Broader sentiment on X positions HIMS as a leader in disrupting the massive healthcare industry. Discussions often praise its subscription model and AI-driven personalization as key strengths. The chatter reflects a belief among many that the company is poised for significant future gains.
Note: This discussion summary was generated from an AI condensation of post data.
Hims & Hers Health Insider Trading Activity
Hims & Hers Health insiders have traded $HIMS stock on the open market 87 times in the past 6 months. Of those trades, 0 have been purchases and 87 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:
- ANDREW DUDUM (Chief Executive Officer) has made 0 purchases and 39 sales selling 1,668,525 shares for an estimated $86,780,236.
- OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 13 sales selling 369,364 shares for an estimated $20,394,289.
- MICHAEL CHI (Chief Commercial Officer) has made 0 purchases and 13 sales selling 91,401 shares for an estimated $5,410,838.
- PATRICK HARRISON CARROLL (Chief Medical Officer) has made 0 purchases and 2 sales selling 70,021 shares for an estimated $3,720,938.
- SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 13 sales selling 37,898 shares for an estimated $2,039,953.
- MELISSA BAIRD (Chief Operating Officer) has made 0 purchases and 4 sales selling 33,333 shares for an estimated $1,867,376.
- IRENE BECKLUND (PAO) has made 0 purchases and 3 sales selling 21,966 shares for an estimated $1,203,032.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Hims & Hers Health Congressional Stock Trading
Members of Congress have traded $HIMS stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN purchased up to $15,000 on 08/04.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Hims & Hers Health Hedge Fund Activity
We have seen 310 institutional investors add shares of Hims & Hers Health stock to their portfolio, and 234 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS added 18,559,302 shares (+inf%) to their portfolio in Q2 2025, for an estimated $925,181,204
- JPMORGAN CHASE & CO added 15,045,710 shares (+549.0%) to their portfolio in Q3 2025, for an estimated $853,392,671
- D. E. SHAW & CO., INC. removed 4,143,604 shares (-68.7%) from their portfolio in Q2 2025, for an estimated $206,558,659
- INVESCO LTD. added 2,128,587 shares (+502.2%) to their portfolio in Q2 2025, for an estimated $106,110,061
- CONTRARIUS GROUP HOLDINGS LTD removed 1,749,968 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $87,235,904
- CLEAR STREET LLC added 1,676,667 shares (+inf%) to their portfolio in Q2 2025, for an estimated $83,581,849
- NORGES BANK added 1,574,009 shares (+inf%) to their portfolio in Q2 2025, for an estimated $78,464,348
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Hims & Hers Health Analyst Ratings
Wall Street analysts have issued reports on $HIMS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Underperform" rating on 11/04/2025
- BTIG issued a "Buy" rating on 11/04/2025
- Canaccord Genuity issued a "Buy" rating on 09/12/2025
To track analyst ratings and price targets for Hims & Hers Health, check out Quiver Quantitative's $HIMS forecast page.
Hims & Hers Health Price Targets
Multiple analysts have issued price targets for $HIMS recently. We have seen 6 analysts offer price targets for $HIMS in the last 6 months, with a median target of $52.5.
Here are some recent targets:
- Allen Lutz from B of A Securities set a target price of $32.0 on 11/04/2025
- David Larsen from BTIG set a target price of $85.0 on 11/04/2025
- Maria Ripps from Canaccord Genuity set a target price of $68.0 on 09/12/2025
- Jailendra Singh from Truist Securities set a target price of $37.0 on 08/18/2025
- Craig Hettenbach from Morgan Stanley set a target price of $40.0 on 06/11/2025
- Ryan MacDonald from Needham set a target price of $65.0 on 06/04/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
